GLP-1 developer Kailera, proteomics firm Alamar file for U.S. IPOs

What: Kailera and Alamar have filed for U.S. initial public offerings (IPOs), marking a significant milestone in their growth trajectories.
Why: The move is expected to raise capital for further research and development of their respective technologies, including Kailera's GLP-1 treatments and Alamar's proteomics platforms.
Signal: The IPO filings signal a growing interest in biotechnology and healthcare investments, with both companies poised to tap into a lucrative market.
Target: The companies are targeting a valuation of around **$2 billion** for Kailera and **$1.5 billion** for Alamar, although these figures are subject to change.
Risk: The IPOs carry a moderate risk, as the companies will need to navigate a competitive market and demonstrate the effectiveness of their technologies to attract investors.